Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
NEWARK, Calif., March 03, 2016 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9 and at the 28th Annual ROTH Conference on Wednesday, March 16.
| Cowen and Company 36th Annual Health Care Conference | |||||
| Date: | Wednesday, March 9 | ||||
| Time: | 9:20am – 9:50am Eastern Time | ||||
| Place: | Boston Marriott Copley Place, Boston, MA | ||||
| Webcast: | http://ir.cymabay.com/events | ||||
| 28th Annual ROTH Conference | |||||
| Date: | Wednesday, March 16 | ||||
| Time: | 10:00am – 10:30am Pacific Time | ||||
| Place: | The Ritz Carlton, Orange County, CA | ||||
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
